A New Cochrane Review Will Evaluate the Next Frontier in…

A New Cochrane Review Will Evaluate the Next Frontier in Cystic Fibrosis Treatment, Fixing the Genetic Defect Itself CFTR modulator drugs have genuinely transformed cystic fibrosis care in recent years, but they only work for about 95% of genetic variants causing the disease, leaving a meaningful group of patients without an effective targeted treatment option. A newly published Cochrane protocol outlines how researchers plan to rigorously evaluate the next generation of therapies designed to address this exact gap, nucleic acid based therapies. Cystic fibrosis is caused by mutations affecting a protein called CFTR, responsible for transporting salts across cell membranes, particularly in the lungs, pancreas, and other organs. In the lungs specifically, this defect leads to thickened mucus, chronic infection, and progressive lung damage. Over 2,000 different genetic variants have been identified, each affecting CFTR production or function differently, which is why some patients respond well to existing modulator drugs while others simply don't have a variant these drugs were designed to target. How current treatments work, and their key limitation: Existing CFTR modulator drugs work by improving the function of whatever CFTR protein a patient's cells already produce, essentially helping a flawed protein work better. What they don't do is correct the ac